Acquired Resistance to Drugs Targeting Tyrosine Kinases

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Advances in Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/bs.acr.2018.02.003PMID 29551130PMCID PMC5985159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis.

  2017cited by this paper
• An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.

  2016cited by this paper
• Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance

  2016cited by this paper
• Microenvironmental regulation of therapeutic response in cancer.

  2015cited by this paper
• Using ancient protein kinases to unravel a modern cancer drug’s mechanism

  2015cited by this paper
• Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

  2015cited by this paper
• The ErbB/HER family of protein-tyrosine kinases and cancer.

  2014cited by this paper
• Energetic dissection of Gleevec’s selectivity towards human tyrosine kinases

  2014cited by this paper
• Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2

  2013cited by this paper
• Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion.

  2013cited by this paper
• Explaining why Gleevec is a specific and potent inhibitor of Abl kinase

  2013cited by this paper
• Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with rapamycin by the pediatric preclinical testing program

  2012cited by this paper
• The extracellular matrix: A dynamic niche in cancer progression

  2012cited by this paper
• Accessories to the crime: functions of cells recruited to the tumor microenvironment.

  2012cited by this paper
• Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.

  2012cited by this paper
• Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

  2012cited by this paper
• The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells

  2012cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance*

  2011cited by this paper
• IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.

  2011cited by this paper
• Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance

  2011cited by this paper
• Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma

  2011cited by this paper
• Insulin-like Growth Factor-1 Receptor Transactivation Modulates the Inflammatory and Proliferative Responses of Neurotensin in Human Colonic Epithelial Cells*

  2011cited by this paper
• Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells

  2011cited by this paper
• Tyrosine kinase-independent activation of extracellular-regulated kinase (ERK) 1/2 by the insulin-like growth factor-1 receptor.

  2011cited by this paper
• The type 1 insulin-like growth factor receptor and resistance to DACH1

  2011cited by this paper
• Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

  2011cited by this paper
• Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.

  2011cited by this paper
• Towards novel paradigms for cancer therapy

  2011cited by this paper
• Mechanisms of drug resistance in kinases

  2011cited by this paper
• Drugging drug resistance.

  2010cited by this paper
• A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

  2010cited by this paper
• Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.

  2010cited by this paper
• The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.

  2010cited by this paper
• EGFR/Met association regulates EGFR TKI resistance in breast cancer

  2010cited by this paper
• Defining the pathway to insulin-like growth factor system targeting in cancer.

  2010cited by this paper
• Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation‐targeted lung cancer therapy

  2010cited by this paper
• Dependence receptors: a new paradigm in cell signaling and cancer therapy

  2010cited by this paper
• Dependence Receptors: The Trophic Theory Revisited

  2010cited by this paper
• A Kinase-Independent Role for Unoccupied Insulin and IGF-1 Receptors in the Control of Apoptosis

  2010cited by this paper
• Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer

  2010cited by this paper
• Histone deacetylase inhibitors in cancer therapy.

  2009cited by this paper
• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• Targeting the phosphoinositide 3-kinase pathway in cancer

  2009cited by this paper
• Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

  2009cited by this paper
• Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

  2009cited by this paper
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

  2008cited by this paper
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

  2008cited by this paper
• Mechanisms of Disease: cancer stem cells—targeting the evil twin

  2008cited by this paper
• Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

  2008cited by this paper
• The retinoblastoma binding protein RBP2 is an H3K4 demethylase.

  2007cited by this paper
• Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma.

  2007cited by this paper
• c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

  2007cited by this paper
• Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism

  2007cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells

  2007cited by this paper
• Anticancer activities of histone deacetylase inhibitors

  2006cited by this paper
• Hypoxia-Inducible Factor-1-Dependent and -Independent Regulation of Insulin-Like Growth Factor-1-Stimulated Vascular Endothelial Growth Factor Secretion

  2006cited by this paper
• Paradoxical effects of the phage display-derived peptide antagonist IGF-F1-1 on insulin-like growth factor-1 receptor signaling.

  2006cited by this paper
• Erlotinib: Optimizing Therapy with Predictors of Response?

  2006cited by this paper
• Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells

  2006cited by this paper
• Herceptin: mechanisms of action and resistance.

  2006cited by this paper
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

  2005cited by this paper
• In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.

  2005cited by this paper
• Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.

  2005cited by this paper
• Oncogenes and Tumor Suppressors (795 articles)

  2004cited by this paper
• A new therapeutic antibody masks ErbB2 to its partners.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase*

  2004cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.

  2004cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

  2004cited by this paper
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

  2003cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

  2000cited by this paper
• Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

  2000cited by this paper
• Characterization of the retinoblastoma binding proteins RBP1 and RBP2.

  1993cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types

  year unknowncited by this paper

• Histone demethylase KDM6B inhibitor GSK-J4 sensitizes glioma cells to tyrosine kinase inhibitor anlotinib in vitro by reducing PDGFRA expression

  2026cites this paper
• Transcriptomic profiling of autophagy and apoptosis pathways in liver cancer cells treated with a new tyrosine kinase inhibitor PD161570

  2025cites this paper
• Comprehensive transcriptome, miRNA and kinome profiling identifies new treatment options for personalized lung cancer therapy

  2025cites this paper
• 2-Amino-4,6-diarylpyrimidines as potential chronic myeloid leukemia cell inhibitors targeting anti-ABL1 kinase: microwave-assisted synthesis, biological evaluation, molecular docking, and dynamics studies

  2025cites this paper
• Targeting Senescent Stemlike Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.

  2025cites this paper
• Machine Learning and Integrative Structural Dynamics Identify Potent ALK Inhibitors from Natural Compound Libraries

  2025cites this paper
• Overcoming Multidrug Resistance in Cancer Cells Targeting ABC Transporter ABCB1 with Tyrosine Kinase Inhibitor: Olverembatinib.

  2025cites this paper
• Translational Insights into Focal Adhesion Kinase Inhibition for Non-Small-Cell Lung Cancer

  2025cites this paper
• Harnessing nanotechnology for efficient delivery of indole-based drugs in cancer treatment.

  2025cites this paper
• Sentrin/SUMO-specific protease 1 contributes to drug resistance in melanoma by mediating the deSUMOylation of Yes-associated protein

  2025cites this paper
• Cancer Therapy Resistance: Choosing Kinase Inhibitors

  2024cites this paper
• TFE3-splicing factor fusions represent functional drivers and druggable targets in translocation renal cell carcinoma.

  2024cites this paper
• The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia.

  2024cites this paper
• ALDOA coordinates PDE3A through the β-catenin/ID3 axis to stimulate cancer metastasis and M2 polarization in lung cancer with EGFR mutations.

  2024cites this paper
• From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

  2024cites this paper
• Targeted dephosphorylation of SMAD3 as an approach to impede TGF-β signaling

  2024cites this paper
• Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System

  2024cites this paper
• Novel antileukemic compound with sub-micromolar potency against STAT5 addicted myeloid leukemia cells.

  2024cites this paper
• The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance

  2024cites this paper
• Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents

  2024cites this paper
• Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation

  2024cites this paper
• The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy.

  2023cites this paper
• Indole Antitumor Agents in Nanotechnology Formulations: An Overview

  2023influential citation
• Cellular signaling pathways as plastic, proto-cognitive systems: Implications for biomedicine

  2023cites this paper
• Elucidating the potential effects of point mutations on FGFR3 inhibitor resistance via combined molecular dynamics simulation and community network analysis

  2023cites this paper
• Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics

  2023cites this paper
• Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition

  2023cites this paper
• Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors

  2023cites this paper
• A biophysical framework for double-drugging kinases

  2023cites this paper
• Receptor tyrosine kinase inhibitors in cancer

  2023cites this paper
• Unraveling Extremely Damaging IRAK4 Variants and Their Potential Implications for IRAK4 Inhibitor Efficacy

  2023cites this paper
• Shifting the Antibody-Drug Conjugate Paradigm: A Trastuzumab-Gold-Based Conjugate Demonstrates High Efficacy against Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Mouse Model.

  2023cites this paper
• Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics

  2023cites this paper
• Perturbations in 3D genome organization can promote acquired drug resistance.

  2023cites this paper
• Association of CYP3A5*3, CYP3A4*18 & CYP2B6*6 polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients

  2023cites this paper
• Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories

  2023cites this paper
• Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams

  2023cites this paper
• A biophysical framework for double-drugging kinases

  2023cites this paper
• Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

  2022cites this paper
• Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer Therapy.

  2022cites this paper
• Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

  2022cites this paper
• 1,3‐diarylpyrazolones as potential anticancer agents for non‐small cell lung cancer: Synthesis and antiproliferative activity evaluation

  2022cites this paper
• Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)

  2022cites this paper
• In silico, Synthesis and Anticancer Evaluation of Benzamide Tryptamine Derivatives as Novel eEF2K Inhibitors.

  2022cites this paper
• Targeting Src-Hic-5 Signal Cascade for Preventing Migration of Cholangiocarcinoma Cell HuCCT1

  2022cites this paper
• A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach

  2022cites this paper
• Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy

  2022cites this paper
• Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts

  2022cites this paper
• Effect of membrane lipid fluidity, composition, and charge on the ability of the antimicrobial peptide ascaphin-8 to insert into the membrane and form pores.

  2022cites this paper
• Characterizing the molecular heterogeneity of clear cell renal cell carcinoma subgroups classified by miRNA expression profile

  2022cites this paper
• Genome-wide CRISPR/Cas9 Screens Reveal Shared and Bespoke Mechanisms of Resistance to SHP2 inhibition

  2022cites this paper
• Perturbations in 3D genome organization can promote acquired drug resistance

  2021cites this paper
• Evaluation of the anticancer activity of dipyridamole and Imatinib mesylate compounds against breast cancer cell line and related biochemical and genetic changes

  2021cites this paper
• Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition

  2021cites this paper
• Metformin synergistically increases the anticancer effects of lapatinib through induction of apoptosis and modulation of Akt/AMPK pathway in SK-BR3 breast cancer cell line

  2021cites this paper
• Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?

  2021cites this paper
• LncRNAs in the Regulation of Genes and Signaling Pathways through miRNA-Mediated and Other Mechanisms in Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Structure-guided machine learning prediction of drug resistance mutations in Abelson 1 kinase

  2021cites this paper
• Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin β3/SRC pathway

  2021cites this paper
• Future epigenetic treatment strategies

  2021cites this paper
• Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer

  2021cites this paper
• Ca2+/calmodulin-dependent Protein Kinases in Leukemia Development

  2021cites this paper
• Multi-targeting siRNA nanoparticles for simultaneous inhibition of PI3K and Rac1 in PTEN-deficient prostate cancer

  2021cites this paper
• Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells

  2021cites this paper
• Single-cell RNA sequencing in human lung cancer: Applications, challenges and pathway towards personalized therapy.

  2021cites this paper
• Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy

  2021cites this paper
• A Pharmacological Analysis of the Activity and Failure of the Medical Treatment of High-Grade Osteosarcoma

  2021cites this paper
• Nanomedicines blocking adaptive signals in cancer cells overcome tumor TKI resistance.

  2020cites this paper
• Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?

  2020cites this paper
• Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome

  2020cites this paper
• Insights Into the Mechanism of Anticancer Drug Imatinib Revealed Through Multi-Omic Analyses in Yeast

  2020cites this paper
• The systemic hallmarks of cancer

  2020cites this paper
• Overcoming Compensatory Mechanisms toward Chronic Drug Administration to Ensure Long-Term, Sustainable Beneficial Effects

  2020cites this paper
• A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance

  2020cites this paper
• The Continuing Evolution of Insulin-like Growth Factor Signaling

  2020cites this paper
• Allosteric inhibitors of the STAT3 signaling pathway.

  2020cites this paper
• Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice

  2020cites this paper
• PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

  2019cites this paper
• Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines

  2019cites this paper
• Exploring Gatekeeper Mutations in EGFR through Computer Simulations

  2019cites this paper
• Transporter and protease mediated delivery of platinum complexes for precision oncology

  2019cites this paper
• Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway

  2019cites this paper
• Lenvatinib-zinc phthalocyanine conjugates as potential agents for enhancing synergistic therapy of multidrug-resistant cancer by glutathione depletion.

  2019cites this paper
• Repurposing of Drugs Targeting YAP-TEAD Functions

  2018cites this paper